This is a micro-learning module summary of a presentation by Dr. Philip Mease, Dr. Alice Gottlieb, and Dr. Joseph Merola which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent medical educational grant from Lilly. This online education program has been designed for healthcare professionals in the US and Europe (excluding the UK).

The "Obesity–Inflammation" Axis and Assessment of Disease Activity

• Clinical Impact of Obesity (Prevalence ~40%): Up to 40% of patients with PsA are affected by obesity (approximately twice as common as in rheumatoid arthritis), which is associated with a 2.5 to 3-fold higher likelihood of inadequate response to biologics.

• The Active Role of Adipose Tissue: Adipose tissue is not passive but a metabolically active inflammatory organ. It promotes systemic inflammation through the altered secretion of adipokines and cytokines:

  • TNF-alpha: Secretion is increased, which drives synovial inflammation and potentially reduces the response to TNF inhibitors.
  • Interleukin-6 (IL-6): Production is increased, which raises C-reactive protein (CRP) levels and increases disease activity.
  • Leptin and Resistin: Increased levels promote proinflammatory TH17 polarization and insulin resistance, thereby intensifying systemic inflammation.
  • Adiponectin: Production of this anti-inflammatory hormone is decreased in obesity, leading to a loss of its protective effect.

• Disease Activity Interpretation Matrix: To prevent premature or inappropriate immunomodulatory drug escalation, clinicians must evaluate patients across four metabolic and inflammatory quadrants:

  • High BMI / Low Inflammation: Symptoms may be mistakenly attributed to uncontrolled peripheral arthritis, potentially leading to unnecessary escalation of biologic therapy while the underlying metabolic trigger is overlooked.
  • High BMI / High Inflammation (Highest-Risk Zone): There is an ambiguous and mixed signal here, where active synovitis and obesity-related inflammation coexist. An automatic switch to biologic therapy should be avoided until the effects of both factors have been carefully assessed.
  • Low BMI / Low Inflammation: Composite scores are highly reliable and reflect true, well-controlled disease activity.
  • Low BMI / High Inflammation: Confirms to the physician that the strong inflammatory signal primarily originates from joint or synovial structures, justifying optimization of immunomodulation.

• Supplement to Total Scores: Because obesity artificially inflates patient tenderness assessments, composite scores (e.g., DAPSA) can be misleading. Objective markers, such as CRP levels and advanced imaging (ultrasound or MRI), should be integrated to distinguish active synovitis from weight-bearing mechanical joint stress.

Individual Treatment Strategies and Latest Findings from Clinical Trials

• Impact of Weight Loss on Minimal Disease Activity: Successful weight loss is directly linked to achieving therapeutic goals. Clinical data show that the probability of achieving such an outcome increases significantly with the extent of weight loss:

  • <5% Weight Loss: 23.1% success rate.
  • 5%–10% Weight Loss: 44.8% success rate.
  • >10% Weight Loss: 59.5% success rate (Odds Ratio: 6.67).

• The TOGETHER-PsA Phase 3b Study: This 52-week randomized study examined 271 overweight/obese adults with highly active PsA, comparing ixekizumab (an IL-17A inhibitor) in combination with tirzepatide (a dual GLP-1/GIP receptor agonist) against ixekizumab monotherapy.

  • Primary Endpoint (Week 36): Simultaneous achievement of an ACR50 response and weight reduction of ≥10% was reached by 31.7% of patients in the combination group compared to 0.8% in the monotherapy group (P < 0.001).
  • Secondary Endpoints: The combination group achieved significantly higher ACR50 values (33.5% vs. 20.4%, P = 0.02) and MDA rates (26.3% vs. 15.3%, P < 0.05), as well as superior improvements in physical functioning and quality of life.
  • Anti-inflammatory Synergy: Notably, a difference in ACR50 values appeared after just 4 weeks – before significant weight loss occurred – suggesting direct anti-inflammatory signaling or cytokine modulation via GLP-1 receptors on immune cells.

• Clinical Decision Scheme (Step-by-Step Guide):

  1. Step 1 (Assessment): Determination of the predominant pathophysiology

     • Active synovitis via imaging/CRP.
     • Is there a mixed clinical picture caused by obesity, or are the symptoms purely metabolic/adipokine-mediated?

  2. Step 2 (Evaluation): Documentation of weight progression

     • Review of lifestyle changes, medication-based obesity therapy, or current use of GLP-1 receptor agonists.

  3. Step 3 (Decision): If there is no active synovitis and metabolic optimization has not yet been sufficiently attempted, escalation of immunomodulatory therapy should be postponed. Instead, the focus should be on weight loss, and the joints should be re-evaluated in 3–6 months.

Patient-Centered Communication Strategies

• Stigmatization and Patient Perspective: The topic of weight is emotionally sensitive; many patients report significant burdens or frustrations due to previous doctor visits. Physicians should avoid presenting obesity as a personal failure regarding lifestyle or discipline and instead define it as a bidirectional biological disease modifier.

• Key Communication Principles:

  • Use Collaborative Openings: Always obtain express consent before introducing the topic of body weight into the conversation.
  • Focus on Metabolic and Joint Health: Explicitly link weight reduction to the relief of symptoms, the reduction of systemic inflammatory load, and the lowering of mortality due to cardiovascular risk factors.
  • Practical Recommendation on Timing: If a patient is highly symptomatic, in severe pain, or in emotional distress during an initial visit, focus exclusively on the immediate stabilization of joints and skin first. Postpone detailed discussions about metabolism and obesity treatment to the second or a later appointment, once a therapeutic rapport has been established.

• Examples of Action-Oriented Phrasing:

  • Avoid Stigmatizing Phrasing: "You need to lose weight – it is making your PsA worse" or "Have you tried going on a diet or exercising more?".
  • Use Phrasing Like: "Is it okay if we talk about how your metabolic health relates to your PsA?" or "Some of the causes of your symptoms may be due to inflammation related to your body weight. Can we explore that together?"

Coordinated Care Pathways and Integration of Systemic Obesity Therapy

• Strategic Classification by BMI Thresholds: Care coordination processes are systematically aligned with the severity of the patient's metabolic profile:

  • BMI 30–34: Primarily rheumatology-led. The focus is on optimizing immunomodulatory therapies in conjunction with basic nutrition, diet, and exercise counseling.
  • BMI 35–39: Transition to a shared care model. The rheumatologist initiates discussions about metabolism and monitors progress while actively collaborating with primary care physicians or endocrinologists to monitor and optimize obesity therapies, blood pressure, and early blood sugar control.
  • BMI > 40: Requires formal referral to a multidisciplinary team (MDT). The rheumatologist ensures adequate treatment of peripheral joints and potentially the spine, while specialists in obesity medicine or bariatric surgeons should lead advanced weight loss strategies.

• Handling Modern Obesity Therapies (GLP-1/GIP Receptor Agonists):

  • Titration During Adverse Events: While overall discontinuation rates in studies due to gastrointestinal events are low (~3%), 20-30% of patients experience transient side effects such as nausea, diarrhea, constipation, or delayed gastric emptying. Dosing must therefore be increased gradually to improve long-term tolerability for the patient.
  • Collaboration Infrastructure: Physicians should utilize resources available in the clinic – such as pharmacy staff, nurse practitioners, and patient support programs – to handle the paperwork for prior authorizations, implement systematic titration schedules, and monitor patient tolerability in everyday life.
  • Reassuring Monitoring Profiles: Concomitant prescription of systemic therapies for obesity together with standard biologics for PsA (e.g., IL-17 or IL-23 inhibitors) does not cause any additional burden regarding laboratory or safety monitoring beyond standard requirements.

Content is accurate as of the date of release.